210 related articles for article (PubMed ID: 33625572)
1. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM; Blum KA
Cancer; 2020 Mar; 126(6):1235-1242. PubMed ID: 31821549
[TBL] [Abstract][Full Text] [Related]
5. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
13. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Batgi H; Merdin A; Dal MS; Kızıl Çakar M; Yıldız J; Başçı S; Uncu Ulu B; Yiğenoğlu TN; Darçın T; Şahin D; Bakırtaş M; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Dec; 26(8):1857-1863. PubMed ID: 32098553
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Park BB; Kim WS; Suh C; Hong JY; Yang DH; Lee WS; Do YR; Koh YI; Won JH; Kim MK; Jo JC; Hyun SY; Kim JA; Oh YH; Lee SS
Leuk Lymphoma; 2019 Dec; 60(13):3251-3257. PubMed ID: 31170847
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
18. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
[TBL] [Abstract][Full Text] [Related]
19. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
